Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Go Girls! Fitness Support Group Intervention Effectiveness Study

Conditions:   Polycystic Ovary Syndrome;   Abnormal Weight Gain;   Excess Weight;   Insulin Resistance;   Premature Adrenarche;   Type 2 Diabetes Mellitus
Intervention:   Behavioral: Go Girls! Fitness Support Group
Sponsors:   University of Virginia;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified April 2014

Can Vitamin D Supplementation Prevent Type 2 Diabetes?

Condition:   Type 2 Diabetes Mellitus
Interventions:   Dietary Supplement: Vitamin D;   Dietary Supplement: Placebo
Sponsors:   Monash University;   Victoria University, Australia;   University of Auckland, New Zealand
Not yet recruiting - verified April 2014

Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Liraglutide;   Drug: Placebo
Sponsors:   Vastra Gotaland Region;   Novo Nordisk A/S
Active, not recruiting - verified April 2014

Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Ertugliflozin 15 mg
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Not yet recruiting - verified April 2014

A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: LY2409021;   Drug: Sitagliptin;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified April 2014

Study to Identify Adequate Biomarker to Detect Vitamin B12 Deficiency in Type 2 Diabetic Patients Treated With Metformin

Condition:   Diabetes Mellitus Type 2
Interventions:   Other: Questionnaire administration;   Other: Laboratory biomarker analysis
Sponsors:   University Hospital, Basel, Switzerland;   University of Basel;   Solothurner Spitäler AG
Recruiting - verified April 2014

Progression of Coronary Atherosclerosis in Asymptomatic Diabetic Subjects

Conditions:   Type 2 Diabetes;   Coronary Artery Disease
Intervention:  
Sponsors:   British Cardiac Research Trust;   Royal Free Hospital NHS Foundation Trust;   North West London Hospitals NHS Trust;   Barnet and Chase Farm Hospitals NHS Trust;   Diabetes and Obesity Research Network;   Lund University;   Health Diagnostic Laboratory, Inc.
Recruiting - verified April 2014

RetroMASTER - Retrospective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes

Condition:   Diabetes
Intervention:  
Sponsors:   NIHR Exeter Clinical Research Facility;   University of Exeter;   Royal Devon and Exeter NHS Foundation Trust;   University of Oxford;   Oxford University Hospitals NHS Trust;   University of Dundee;   NHS Tayside
Recruiting - verified April 2014

Effect of Implantable Contraception on Type-2 DM and Metabolic Syndrome in Women With History of Gestational DM

Conditions:   Diabetes Mellitus;   Metabolic Syndrome
Intervention:   Device: progestin implant
Sponsor:   Mahidol University
Active, not recruiting - verified April 2014

Is There Room for Butter in a Healthy Diet?

Condition:   Atherosclerosis
Interventions:   Other: Danish butter;   Other: Olive oil
Sponsors:   University of Copenhagen;   The Danish Dairy Research Foundation, Denmark
Completed - verified April 2014

Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function.

Condition:   Focus Type 2 Diabetes Related Chronic Kidney Disease
Intervention:   Behavioral: Exercise
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified April 2014

Validation of a Patient Decision Aid for Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Behavioral: Use of a PDA to assist shared decision making
Sponsor:   EPI-Q
Not yet recruiting - verified April 2014

PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA

Conditions:   Diabetes Mellitus, Non-Insulin-Dependent;   Hypertriglyceridemia
Interventions:   Drug: Metformin Eicosapentaenoate;   Drug: Metformin HCl and Vascepa
Sponsor:   Thetis Pharmaceuticals LLC
Recruiting - verified April 2014

A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin Peglispro;   Drug: Insulin Glargine
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified April 2014

Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Saxagliptin 5mg;   Drug: Placebo for Saxagliptin
Sponsors:   AstraZeneca;   Bristol-Myers Squibb
Not yet recruiting - verified April 2014

Investigating Markers of Energy Metabolism in the CNS and Periphery in Pregnant Women With Varying Degrees of Insulin Resistance

Conditions:   Gestational Diabetes;   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   Yale University;   Yale New Haven Hospital
Recruiting - verified April 2014

PROMASTER - PROspective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes

Condition:   Diabetes
Intervention:   Drug: second- or third-line glucose-lowering diabetes treatment
Sponsors:   NIHR Exeter Clinical Research Facility;   University of Exeter;   Royal Devon and Exeter NHS Foundation Trust;   King's College London;   King's College Hospital NHS Trust;   University of Glasgow;   NHS Greater Glasgow and Clyde;   Newcastle University;   Newcastle-upon-Tyne Hospitals NHS Trust
Recruiting - verified April 2014

Relationship Between HbA1c, Fasting Plasma Glucose, Post-prandial Glucose and Other Measures of Glycemic Control

Condition:   Diabetes Mellitus, Type 2
Intervention:   Device: 6-day Continuous Glucose Monitoring System
Sponsor:   University of Malaya
Recruiting - verified April 2014

Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes

Condition:   Diabetes Type 2
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2014

Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion

Condition:   Metabolic Syndrome X
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsor:   University of Guadalajara
Not yet recruiting - verified April 2014

Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects

Condition:   Diabetes Mellitus
Intervention:   Drug: JTT-251 or Placebo
Sponsor:   Akros Pharma Inc.
Recruiting - verified April 2014

A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin degludec/liraglutide;   Drug: insulin aspart
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2014

A Family-Based Diabetes Intervention for Hispanic Adults in an Emerging Community

Condition:   Diabetes
Interventions:   Behavioral: Experimental: Diabetes Self Management;   Behavioral: General Health Education
Sponsors:   University of North Carolina, Greensboro;   National Institutes of Health (NIH)
Recruiting - verified April 2014

Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus

Conditions:   Type 2 Diabetes Mellitus;   Insulin Sensitivity/Resistance
Interventions:   Drug: Linagliptin;   Drug: Placebo;   Drug: Voglibose
Sponsor:   Postgraduate Institute of Medical Education and Research
Recruiting - verified April 2014

Ertugliflozin and Sitagliptin Co-administration Factorial Study (MK-8835-005)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Matching Placebo to Ertugliflozin 5 mg;   Drug: Matching Placebo to Ertugliflozin 10 mg;   Drug: Matching Placebo to sitagliptin 100 mg;   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 10 mg;   Drug: Sitagliptin 100 mg;   Drug: Metformin >= 1500 mg/day;   Biological: Insulin Glargine Rescue Medication;   Drug: Glimepiride Rescue Medication
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Not yet recruiting - verified April 2014

Comprehensive Lifestyle Modification for Patients With Hypertension and Metabolic Syndrome: a Multicenter Randomized Controlled Trial

Conditions:   Hypertension;   Metabolic Syndrome
Interventions:   Behavioral: Comprehensive Lifestyle Modification;   Behavioral: DASH
Sponsors:   Universität Duisburg-Essen;   Kliniken Essen-Mitte;   Immanuel Hospital Berlin, Berlin, Germany;   Charité University Medical Center, Berlin, Germany;   University of Witten/Herdecke
Recruiting - verified April 2014

Influence of the Use of the Diabetic Drug Metformin on the Overall Survival and Treatment-related Toxicity in Advanced Stage Non-small Cell Lung Cancer Patients.

Condition:   Non Small Cell Lung Cancer
Intervention:  
Sponsors:   Maastricht Radiation Oncology;   MAASTRO Clinic;   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting - verified April 2014

Common Variation at SLC16A11 and Other Genes on the Response to a Mixed Meal Tolerance Test

Conditions:   Genetics;   Metabolism;   Type 2 Diabetes
Interventions:   Other: Mixed Meal Tolerance Test;   Drug: Metformin
Sponsors:   Massachusetts General Hospital;   Instituto Carlos Slim de la Salud;   Broad Institute of Harvard and MIT
Recruiting - verified April 2014

Impact of Structured Physical Activity Education Delivery in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Behavioral: Physical activity and exercise education and behaviour counseling from a Registered Kinesiologist and a YMCA Wellness Coach;   Behavioral: Unstructured Physical Activity and Exercise
Sponsor:   Royal Victoria Hospital, Canada
Recruiting - verified April 2014

A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden

Conditions:   Diabetes;   Type 2 Diabetes Mellitus
Interventions:   Drug: liraglutide;   Drug: sitagliptin
Sponsor:   Novo Nordisk A/S
Recruiting - verified March 2014

Effect of Linagliptin on Vascular Inflammation in Patients With Type 2 Diabetes Mellitus

Conditions:   Diabetes Mellitus Type 2 (T2DM),;   Vascular Inflammation,;   Plaque Morphology
Interventions:   Drug: Linagliptin;   Drug: Placebo
Sponsor:   RWTH Aachen University
Not yet recruiting - verified April 2014

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Condition:   Healthy
Interventions:   Drug: Canagliflozin, 100 mg;   Drug: Metformin XR, 500 mg;   Drug: CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg;   Drug: CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified April 2014

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Condition:   Healthy Volunteers
Interventions:   Drug: Canagliflozin, 300 mg;   Drug: Metformin XR, 500 mg;   Drug: CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg;   Drug: CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified April 2014

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathies
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Recruiting - verified April 2014

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Condition:   Healthy Volunteers
Interventions:   Drug: Canagliflozin, 100 mg;   Drug: Metformin XR, 500 mg;   Drug: CANA/MET XR FDC, Formulation 1, 50 mg/500 mg;   Drug: CANA/MET XR FDC, Formulation 2, 50 mg/500 mg
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified April 2014

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

Condition:   Type 2 Diabetes
Interventions:   Drug: Insulin glargine/lixisenatide HOE901/AVE0010;   Drug: Insulin glargine HOE901;   Drug: Lixisenatide AVE0010;   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified April 2014

Mitochondrial nt3243 A>G Mutation in Taiwan

Conditions:   MELAS Syndrome;   Noninsulin-dependent Diabetes Mellitus With Deafness
Intervention:  
Sponsors:   National Taiwan University Hospital;   National Cheng-Kung University Hospital
Recruiting - verified April 2014

Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin (5 mg);   Drug: Ertugliflozin (15 mg);   Drug: Placebo;   Drug: Metformin;   Drug: Sitagliptin;   Drug: Glimepiride;   Biological: Insulin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified April 2014

A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 15 mg;   Drug: Placebo to Ertugliflozin;   Other: Glimepiride;   Drug: Placebo to Glimepiride;   Biological: Basal Insulin;   Drug: Metformin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified April 2014

DREAM Project Community Health Worker Intervention

Condition:   Diabetes Mellitus, Type 2
Interventions:   Other: CHW Intervention;   Other: Control - Introductory Educational Session Only
Sponsors:   New York University School of Medicine;   National Center on Minority Health and Health Disparities (NCMHD)
Recruiting - verified April 2014

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2014

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Not yet recruiting - verified April 2014

Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers

Condition:   Insulin Dependent Diabetes Mellitus (Type II Diabetes)
Interventions:   Drug: Sitagliptin;   Drug: Placebo
Sponsors:   Georgetown University;   Merck Sharp & Dohme Corp.
Recruiting - verified April 2014

Group Appointments in Primary Care: A Clinical Group Education Intervention To Improve Diabetes Outcomes

Condition:   Type 2 Diabetes Mellitus (T2DM)
Interventions:   Behavioral: Group Appointments;   Behavioral: Individual Appointments (IAs)
Sponsors:   University of British Columbia;   Ministry of Health, British Columbia
Recruiting - verified April 2014

Circadian Phase Adjustment and Improvement of Metabolic Control in Night Shift Workers

Condition:   Healthy Night Shift Workers, Sleep Disorders
Interventions:   Drug: Melatonin 2mg;   Drug: Placebo
Sponsor:   Universitätsklinikum Hamburg-Eppendorf
Not yet recruiting - verified April 2014

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)

Condition:   Diabetic Nephropathies
Interventions:   Drug: BAY94-8862;   Drug: BAY94-8862;   Drug: BAY94-8862;   Drug: BAY94-8862;   Drug: BAY94-8862;   Drug: Placebo;   Drug: BAY 94-8862;   Drug: BAY 94-8862
Sponsor:   Bayer
Recruiting - verified April 2014

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

Conditions:   Diabetes Mellitus, Type 2;   Albuminuria
Interventions:   Drug: Placebo;   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified April 2014

Trial of Exenatide for Parkinson's Disease

Condition:   Parkinson's Disease
Interventions:   Drug: Exenatide;   Other: Placebo
Sponsor:   University College, London
Not yet recruiting - verified April 2014

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2014

Acute Effects of Moderate Versus High Intensity Exercise on Insulin Sensitivity in Pregnant Women With and Without Gestational Diabetes Mellitus

Condition:   Diabetes, Gestational
Intervention:   Behavioral: exercise
Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital
Recruiting - verified April 2014

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2014

A Study of RO6811135 in Patients With Type 2 Diabetes Who Are Inadequately Controlled With Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RO6811135;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Withdrawn - verified April 2014

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

Conditions:   Diabetes Mellitus, Type 2;   Hypertension
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsor:   Janssen Scientific Affairs, LLC
Recruiting - verified April 2014

BIOFLOW III Asia Registry

Conditions:   Coronary Artery Disease;   Myocardial Ischemia;   Diabetes Mellitus Type 1 or 2
Intervention:  
Sponsor:   BIOTRONIK Asia Pacific Pte Ltd
Recruiting - verified February 2014

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GSK2330672;   Drug: Placebo;   Drug: Metformin
Sponsors:   GlaxoSmithKline;   Elite Research Institute
Completed - verified April 2014

Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: semaglutide;   Drug: oral placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2014

The Effectiveness of Smoking Cessation in Prediabetic Smokers

Conditions:   Diabetes Mellitus;   Cigarette Smoking;   Prediabetes
Interventions:   Other: Smoking cessation;   Behavioral: Self-management
Sponsors:   National Taiwan University Hospital;   National Science Council, Taiwan
Recruiting - verified April 2014

Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: metformin;   Drug: sulfonylurea
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified April 2014

CARMELINA: Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus at High Vascular Risk

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified April 2014

A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)

Condition:   Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Withdrawn - verified April 2014

BIOFLOW-III Israel Satellite Registry

Conditions:   Coronary Artery Disease;   Myocardial Ischemia;   Diabetes Mellitus Type 1 or 2
Intervention:  
Sponsor:   BIOTRONIK Israel
Recruiting - verified July 2013

Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period

Conditions:   Diabetes;   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2;   Healthy
Intervention:   Other: No treatment given
Sponsor:   Novo Nordisk A/S
Enrolling by invitation - verified April 2014

Walnut Consumption, Endothelial Function, and Biomarkers

Conditions:   Coronary Heart Disease;   Type 2 Diabetes
Intervention:   Other: Once ounce per day of walnuts
Sponsor:   Brigham and Women's Hospital
Recruiting - verified April 2014

A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo;   Drug: metformin
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin

Condition:   Type 2 Diabetes Mellitus (T2DM)
Interventions:   Drug: Vildagliptin;   Drug: Metformin;   Drug: sulfonylurea (SU);   Drug: Basal Insulin
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2014

Postpartum Screening of Type 2 Diabetes

Condition:   Type 2 Diabetes
Intervention:   Procedure: oral glucose tolerance test 2 days post-partum
Sponsors:   Université de Sherbrooke;   The Lawson Foundation
Recruiting - verified April 2014

Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)

Condition:   Type 2 Diabetes
Interventions:   Drug: MK-3102;   Drug: Sitagliptin;   Drug: Placebo to MK-3102;   Drug: Placebo to Sitagliptin;   Drug: Open-label Metformin;   Drug: Open-label Glimepiride
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2014

Abnormal Post-partum Glucose Metabolism After Gestational Diabetes Diagnosed Before or After 24 Weeks of Gestation

Conditions:   Gestational Diabetes;   Type 2 Diabetes;   Glucose Intolerance
Intervention:   Biological: Post-partum oral glucose tolerance test
Sponsor:   Centre Hospitalier Universitaire de Nīmes
Recruiting - verified April 2014

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin aspart (FIAsp);   Drug: basal insulin
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified April 2014

Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes.

Condition:   Type 2-diabetes
Interventions:   Drug: Linagliptin;   Drug: Placebo
Sponsor:   University of Erlangen-Nürnberg Medical School
Completed - verified April 2014

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin 100 mg;   Drug: Canagliflozin 300 mg;   Drug: Metformin XR
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified April 2014

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

Condition:   Type 2 Diabetes
Interventions:   Drug: lixisenatide (AVE0010);   Drug: placebo
Sponsor:   Sanofi
Recruiting - verified April 2014

MARLINA - T2DM : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin 5mg
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified April 2014

A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RO6811135;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: BI 10773;   Drug: BI 10773 Placebo;   Drug: BI 10773 / BI 1356;   Drug: BI 10773 / BI 1356;   Drug: BI 10773 / BI 1356 Placebo;   Drug: BI 10773;   Drug: BI 10773;   Drug: BI 10773;   Drug: BI 10773 / BI 1356 Placebo;   Drug: BI 10773;   Drug: BI 10773 / BI 1356 Placebo;   Drug: BI 10773 Placebo;   Drug: BI 10773;   Drug: BI 10773 / BI 1356 Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified April 2014

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Condition:   Type 2 Diabetes
Interventions:   Drug: lixisenatide (AVE0010);   Drug: insulin glulisine (HMR1964)
Sponsor:   Sanofi
Recruiting - verified April 2014

A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: PF-05175157;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2014

Validation of an RLIP76 Assay in Humans

Condition:   Type 2 Diabetes
Intervention:   Other: Blood Draw
Sponsor:   City of Hope Medical Center
Recruiting - verified April 2014

A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Matching placebo to MK-3102;   Drug: Glimepiride;   Drug: Matching placebo to glimepiride;   Drug: Insulin glargine;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified April 2014

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Linagliptin;   Drug: Empagliflozin + Linagliptin;   Drug: Empagliflozin + Linagliptin;   Drug: Empagliflozin + Linagliptin;   Drug: Empaglifozin placebo + Linagliptin placebo;   Drug: Empagliflozin + Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified April 2014

A Study of The Effect of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo;   Drug: metformin
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

Effect of Vitamin D Supplementation on Glucose Tolerance in Subjects at Risk for Diabetes With Low Vitamin D.

Conditions:   Type 2 Diabetes Mellitus;   Vitamin D Deficiency
Interventions:   Dietary Supplement: Control;   Dietary Supplement: Vitamin D
Sponsors:   University of Toronto;   Dairy Farmers of Canada;   Public Health Agency of Canada (PHAC)
Recruiting - verified April 2014

User Evaluation of the MiniMed 620G and 640G Insulin Pumps

Conditions:   Type 1 Diabetes;   Type 2 Diabetes
Intervention:   Device: Medtronic MiniMed 620G or 640G Insulin Pump
Sponsor:   Medtronic Diabetes
Recruiting - verified November 2013

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Conditions:   Diabetes Mellitus, Type 2;   Hyperglycemia
Interventions:   Drug: Empagliflozin low dose qd;   Drug: Metformin 500 mg bid;   Drug: Metformin 1000 mg bid;   Drug: Empagliflozin high dose qd;   Drug: Empagliflozin low dose bid;   Drug: Metformin 500 mg bid;   Drug: Empagliflozin high dose bid;   Drug: Empagliflozin low dose bid;   Drug: Metformin 1000 mg bid;   Drug: Metformin 500 mg bid;   Drug: Metformin 1000 mg bid;   Drug: Empagliflozin high dose bid;   Drug: Metformin 1000 mg bid;   Drug: Empagliflozin high dose bid
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified April 2014

A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy

Condition:   Diabetic Nephropathy
Interventions:   Drug: PF-04634817;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2014

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Condition:   Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022 AM4)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Matching placebo to MK-3012;   Drug: Glimepiride;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2014

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2014

MK-3102 Phase III Clinical Trial - Placebo- and Sitagliptin-controlled Monotherapy Study in Japanese Participants With Type 2 Diabetes Mellitis (MK-3102-020)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Sitagliptin;   Drug: Placebo to MK-3102;   Drug: Placebo to sitagliptin
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified April 2014

Acute Dose Response of Korean White Ginseng in Metabolic Syndrome or Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Metabolic Syndrome
Interventions:   Dietary Supplement: 1 gram of White Korean Ginseng;   Dietary Supplement: 3 grams of White Korean Ginseng;   Dietary Supplement: 6 grams of White Korean Ginseng;   Dietary Supplement: 3 grams of Wheat Bran Control;   Dietary Supplement: 500mg of Korean Red Ginseng
Sponsor:   St. Michael's Hospital, Toronto
Completed - verified April 2014

A Study of MK-3102 in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Placebo to MK-3102;   Drug: Glipizide;   Drug: Placebo to glipizide;   Biological: Insulin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2014

MK-3102 Phase III Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015 AM1)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Matching placebo to MK-3102;   Drug: Basal medication
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified April 2014

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine new formulation (HOE901);   Drug: Insulin glargine (HOE901)
Sponsor:   Sanofi
Completed - verified April 2014

Resistance Training and Testosterone After Spinal Cord Injury

Condition:   Spinal Cord Injury
Interventions:   Procedure: Resistance Training and Testosterone Patches;   Drug: Testosterone Patches
Sponsors:   Department of Veterans Affairs;   Virginia Commonwealth University
Recruiting - verified April 2014

Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes

Condition:   Type 2 Diabetes
Interventions:   Dietary Supplement: Vitamin D3;   Drug: Omega-3 fatty acid (fish oil);   Dietary Supplement: Vitamin D3 placebo;   Drug: Fish oil placebo
Sponsors:   Brigham and Women's Hospital;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting - verified April 2014

An Educational Intervention for Type 2 Diabetes Patients

Condition:   Diabetes Mellitus
Interventions:   Behavioral: Intervention Video;   Behavioral: Control
Sponsor:   Department of Veterans Affairs
Recruiting - verified April 2014

Biomarkers of Diabetic Retinopathy Progression

Conditions:   Type 2 Diabetes Mellitus;   Mild Nonproliferative Diabetic Retinopathy
Intervention:  
Sponsor:   Association for Innovation and Biomedical Research on Light and Image
Active, not recruiting - verified April 2014

Register for Patients With Diabetic Foot Syndrome and Critical Limb Ischemia

Conditions:   Type 2 Diabetes Mellitus;   Diabetic Foot;   Critical Limb Ischemia
Intervention:  
Sponsor:   GWT-TUD GmbH
Terminated - verified April 2014

Vascular Impairment in Type II Diabetes Mellitus With Co-morbid Obstructive Sleep Apnea

Conditions:   Sleep Apnea, Obstructive;   Diabetes Mellitus
Interventions:   Device: Continuous positive airway pressure;   Device: Sham continuous positive airway pressure
Sponsors:   Brigham and Women's Hospital;   Beth Israel Deaconess Medical Center
Recruiting - verified April 2014

Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Vildagliptin
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2014

A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296 AM1)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin/metformin XR;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2014

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Condition:   Prostate Cancer
Interventions:   Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin acetate;   Drug: leuprolide acetate;   Drug: orteronel;   Drug: triptorelin
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2014

Study of RO6807952 in Patients With Diabetes Mellitus Type 2

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RO6807952;   Drug: RO6807952;   Drug: Placebo;   Drug: liraglutide
Sponsor:   Hoffmann-La Roche
Terminated - verified April 2014

Safety and Efficacy of YH14617 in Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Drug: YH14617;   Drug: YH14617;   Drug: YH14617;   Drug: Placebo
Sponsors:   Yuhan Corporation;   Peptron, Inc.
Recruiting - verified April 2014

Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083)

Conditions:   Diabetes Mellitus;   Type 2 Diabetes
Interventions:   Drug: Sitagliptin;   Drug: Metformin;   Drug: Placebo to sitagliptin;   Drug: Placebo to metformin;   Drug: Metformin Rescue;   Drug: Sitagliptin Rescue;   Biological: Insulin Rescue
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2014

"Effect of High Fat and High Glycemic Diets

Condition:   Type 2 Diabetes
Interventions:   Behavioral: High Glycemic Diet;   Behavioral: Control diet
Sponsor:   Mayo Clinic
Recruiting - verified April 2014

Orthogonal Polarisation Study in Young, Elderly and Type 2 Diabetics

Condition:   Type 2 Diabetes Mellitus
Interventions:   Dietary Supplement: Glucose;   Dietary Supplement: Placebo
Sponsor:   Maastricht University Medical Center
Completed - verified April 2014

Relation of Glucose and Acute Pancreatitis

Condition:   Acute Pancreatitis
Intervention:  
Sponsors:   Huashan Hospital;   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Completed - verified April 2014

Identification and Characterization of Monogenic Diabetes

Condition:   Diabetes
Interventions:   Other: Constitution of a biological bank;   Other: Metabolic studies
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting - verified April 2014

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo matching with Saxagliptin;   Drug: Metformin IR;   Drug: Metformin XR;   Drug: Saxagliptin;   Drug: Saxagliptin
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified April 2014

Liraglutide and Heart Failure in Type 2 Diabetes

Conditions:   Congestive Heart Failure;   Type 2 Diabetes Mellitus
Interventions:   Drug: liraglutide;   Drug: glimepiride;   Drug: Metformin
Sponsors:   Karolinska Institutet;   Thomas Nystrom;   Örebro University, Sweden
Recruiting - verified April 2014

A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: lisinopril;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

Effect of a Low Advanced Glycation End Products (AGE) Diet in the Metabolic Syndrome

Condition:   Metabolic Syndrome
Interventions:   Other: Regular AGE Diet;   Other: Low AGE Diet
Sponsors:   Mount Sinai School of Medicine;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting - verified April 2014

A Study of RO6807952 in Patients With Diabetes Mellitus Type 2

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RO6807952;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study of MIRCERA for the Intrapetient Variability of Hemoglobin Levels in Patients With Chronic Renal Anemia (RIVAL)

Condition:   Anemia
Intervention:  
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (HOE901);   Drug: INSULIN GLULISINE (HMR1964)
Sponsor:   Sanofi
Recruiting - verified April 2014

Local Measures to Prevent Diabetes in the Værnes Region.

Conditions:   Diabetes Mellitus Type 2;   Obesity
Intervention:   Behavioral: Behavioural change programme
Sponsor:   Norwegian University of Science and Technology
Recruiting - verified April 2014

Genetic Testing for Type 2 Diabetes

Condition:   Diabetes Mellitus
Interventions:   Genetic: genetic testing for type 2 diabetes;   Other: Conventional risk counseling for type 2 diabetes
Sponsors:   Department of Veterans Affairs;   Duke University
Completed - verified April 2014

A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: taspoglutide;   Drug: taspoglutide;   Drug: insulin glargine;   Drug: metformin
Sponsor:   Hoffmann-La Roche
Terminated - verified April 2014

A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: pioglitazone
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: taspoglutide;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RO5095932;   Drug: Placebo;   Drug: RO5095932;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study of Single Doses of RO4998452 in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RO4998452;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

High Blood Pressure and Sleep Apnea in Diabetic Macular Edema

Condition:   Diabetic Retinopathy
Interventions:   Behavioral: high blood pressure treatment;   Behavioral: sleep apnea treatment;   Behavioral: diabetic macular edema treatment
Sponsor:   Assistance Publique - Hôpitaux de Paris
Completed - verified April 2014

A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RO5095932;   Drug: RO5095932;   Drug: placebo;   Drug: metformin
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   The George Institute;   Servier
Completed - verified April 2014

A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: RO4998452
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women

Condition:   Diabetes Mellitus Type II Non Insulin Dependent
Interventions:   Dietary Supplement: Vitamin E;   Dietary Supplement: Vitamin C;   Dietary Supplement: Lipid Oxidation
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2014

Effect of Type 2 Diabetes Genetic Risk Information on Health Behaviors and Outcomes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: Standardized Risk Assessment
Sponsors:   Duke University;   deCODE genetics
Completed - verified April 2014

A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: taspoglutide;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RO5093151;   Drug: RO5093151;   Drug: RO5027838;   Drug: RO5027838;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: taspoglutide;   Drug: Placebo;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study of Taspoglutide in Type 2 Diabetic Patients

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: taspoglutide;   Drug: taspoglutide;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RO4998452;   Drug: RO4998452;   Drug: RO4998452;   Drug: RO4998452;   Drug: RO4998452;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

Validation of a Predictive Model to Estimate the Risk of Conversion to Clinically Significant Macular Edema and/or Vision Loss in Mild Nonproliferative Diabetic Retinopathy in Diabetes Type 2

Condition:   Diabetic Retinopathy
Intervention:  
Sponsors:   Association for Innovation and Biomedical Research on Light and Image;   Fundação para a Ciência e Tecnologia
Completed - verified April 2014

A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: taspoglutide;   Drug: taspoglutide;   Drug: insulin glargine;   Drug: metformin
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: taspoglutide;   Drug: taspoglutide;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: taspoglutide;   Drug: taspoglutide;   Drug: placebo;   Drug: pioglitazone;   Drug: metformin
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: taspoglutide;   Drug: taspoglutide;   Drug: exenatide
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Lixisenatide (AVE0010);   Device: Pen auto-injector;   Drug: Exenatide;   Device: Prefilled pen injector;   Drug: Metformin
Sponsor:   Sanofi
Completed - verified April 2014

A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RO4998452;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

Pharmacist-led Group Medical Visits to Help With Diabetes Management

Conditions:   Diabetes Mellitus;   Cardiovascular Diseases
Interventions:   Other: Algorithm driven medication titration;   Behavioral: Monitoring;   Behavioral: Group support;   Behavioral: Self efficacy
Sponsor:   Department of Veterans Affairs
Completed - verified April 2014

A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RG1511;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study of DPP-IV (3) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RO4876904;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: Actos
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study of Aleglitazar in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: Actos;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Glyburide
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Drug-Drug Interaction Study of GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Simvastatin
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: GK Activator (2)
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: GK Activator (2)
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Metformin
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Metformin
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

Insulin Treatment Variation in Southwestern Diabetics

Conditions:   Diabetes;   Self-Monitoring, Blood Glucose
Intervention:  
Sponsor:   Department of Veterans Affairs
Completed - verified April 2014

Diabetes Telemedicine Project

Conditions:   Diabetes Mellitus Type 2;   Diabetes Mellitus, Type 1
Interventions:   Behavioral: The Diabetes Treatment Satisfaction Questionnaire;   Behavioral: Diabetes Empowerment Scale;   Behavioral: CBOC's undergo half-day joint-clinics via teleconference
Sponsor:   Department of Veterans Affairs
Completed - verified April 2014

A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: DPP-IV Inhibitor;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: DPP-IV Inhibitor;   Drug: Placebo;   Drug: Metformin
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

Urinary Vitamin C Loss in Diabetic Subjects

Condition:   Diabetes Mellitus
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified June 2013

Get CardioSmart

You're Invited